NeoGenomics Q2 Revenues Rise on Genetic Test Volume Growth

Jul 26, 2016

This article has been updated to include comments from NeoGenomics' earnings call.

NEW YORK (GenomeWeb) – NeoGenomics today reported year over year growth of 159 percent in its second quarter revenues driven by an increase in clinical genetic testing volume.

For the three-month period ended June 30, the company posted revenues of $63.1 million compared with $24.4 million a year earlier.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Menu

NeoGenomics Q2 Revenues Rise on Genetic Test Volume Growth

To read the full story....

Breaking News

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

In Brief This Week: Invivoscribe, Todos Medical, Personalis, and More

FDA Approves CD Diagnostics' Test for Prosthetic Joint Infections

FDA Clears InBios International Zika Antibody Test

Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

Featured White Papers

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Clinical Genomics of NTRK Fusion Detection in Cancer

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

Startup Novel Microdevices Developing Rapid Point-of-Care MDx System for STIs

Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

FDA Clears Cepheid, Hologic CT/NG Assays for Extragenital Testing

Roche Obtains FDA Clearance for Sexually Transmitted Disease Test

Sponsorships